Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment

Journal of Infection

Volumn 54, Issue 2, 2007, Pages 159-166

  Sanchez, Rosario ^a   Portilla, Joaquín ^a   Gimeno, Adelina ^a   Boix, Vicente ^a   Llopis, Coral ^a   Sanchez Paya, Jose ^a   Merino, Esperanza ^a   de la Sen, Maria Luz ^a   Muñoz, Carlos ^a   Reus, Sergio ^a   Plazas, Joaquín ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

AIDS; Antiretroviral therapy; Highly active; HIV infection; Treatment interruption

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CANCER; CD4+ T LYMPHOCYTE; CELL KINETICS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LACTIC ACIDOSIS; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYNEUROPATHY; SHORT COURSE THERAPY; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33846120953     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.03.029     Document Type: Article

References (38)

1. Li X., Margolick J.B., Conover C.S., Badri S., Riddler S.A., Witt M.D., et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 38 (2005) 320-328
2. Carcelain G., Tubiana R., Samri A., Calvez V., Delaugerre C., Agut H., et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4T-helper cells fail to control virus rebound during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 75 (2001) 234-241
3. Davey Jr. R.T., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., et al. HIV-1 and T-cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96 (1999) 15109-15114
4. Dybul M., Chun T.W., Yoder C., Hidalgo B., Belson M., Hertogs K., et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic and toxicity parameters. Proc Natl Acad Sci USA 98 (2001) 15161-15166
5. Frost S., Martinez-Picado J., Ruiz L., Clotet B., and Leigh Brown A.J. Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 76 (2002) 968-979
6. Garcia F., Plana M., Vidal C., Cruceta A., O'Brien W.A., Pantaleo G., et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15 (2001) F29-F40
7. Taffe P., Rickenbach M., Hirschel B., Opravil M., Furrer H., Janin P., et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: result from a cohort study. AIDS 16 (2002) 747-755
8. Harrigan P.R., Whaley M., and Montaner J.S.G. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13 (1999) 59-62
9. Neumann A.U., Tubiana R., Calvez V., Robert C., Li T.S., Agut H., et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 13 (1999) 677-683
10. Metzner K.J., Bonhoeffer S., Fischer M., Karanicolas R., Allers K., Joos B., et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188 (2003) 1433-1443
11. Dybul M, Nies-Kraske E, Daucher M, Hallahan C, Csako G, Yoder C, et al. A randomized controlled trial of long cycle structured intermittent versus continuous ARV therapy for chronic HIV infection. 10th Conference on Retrovirus and Opportunistic Infections, February 10-14, 2003, Boston, MA, Abstract 68Ib.
12. Ruiz L, Romeu J, Martinez-Picado J, Bellido R, Llibre J, Domingo P, et al. Selection of drug-resistance mutations in chronic HIV-infected patients during therapy interruptions guided by CD4+ T-cell counts and viral load levels: the Tibet study. Conference on Retrovirus and Opportunistic Infections, February 22-25, 2005, Boston, MA, Abstract 679.
13. Lawrence J., Mayers D.L., Hullsiek K.H., Collins G., Abrams D.I., Reisler R.B., et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349 (2003) 837-846
14. Katlama C., Dominguez S., Gourlain K., Duvivier C., Delaugerre C., Legrand M., et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18 (2004) 217-226
15. Ananworanich J., Nuesch R., Le Braz M., Chetchotisakd P., Vibhagool A., Wicharuk S., et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17 (2003) F33-F37
16. Ananworanich J., Siangphoe U., Hill A., Cardiello P., Apateerapong W., Hirschel B., et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 39 (2005) 523-529
17. Tarwater P.M., Parish M., and Gallant J.E. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 37 (2003) 1541-1548
18. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. 13th Conference on Retrovirus and Opportunistic Infections, February 5-8, 2003, Denver, CO, Abstract 106LB.
19. Monforte A.D., Cozzi-Lepri A., Phillips A., De Luca A., Murri R., Mussini C., et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of antiretroviral-naive patients. J Acquir Immune Defic Syndr 38 (2005) 407-416
20. Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., D'Aquila R., et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14 (2000) 2857-2867
21. Chen R.Y., Westfall A.O., Raper J.L., Cloud G.A., Chatham A.K., Acosta E.P., et al. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res Hum Retroviruses 18 (2002) 909-916
22. Poulton M.B., Sabin C.A., and Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS 17 (2003) 126-128
23. Youle M., Janossy G., Turnbull W., Tilling R., Loveday C., Mocroft A., et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS 14 (2000) 1717-1720
24. Giuntini R., Martinelli C., Ambu S., Bartolozzi D., Farese A., Boddi V., et al. Prolonged treatment interruption in chronic HIV infection: a new strategy?. AIDS 19 (2005) 209-211
25. Garcia F., Plana M., Vidal C., Cruceta A., O'Brien W.A., Pantaleo G., et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13 (1999) F79-F86
26. Achenbach C., Till M., Palella F., Knoll M.D., Terp S.M., Kalnins A.U., et al. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA. HIV Med 6 (2005) 7-12
27. Ortiz G.M., Wellons M., Brancato J., Vo H.T., Zinn R.L., Clarkson D.E., et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 98 (2001) 13288-13293
28. Fischer M., Hafner R., Schneider C., Trkola A., Joos B., Joller H., et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 17 (2003) 195-199
29. D'Arminio A., Cozzi-Lepri A., Murri R., Novati R., Antinori A., Arici C., et al. The effect of HAART interruptions on clinical progression: evidence from ICONA cohort. Antivir Ther 8 Suppl. 1 (2003) S219
30. Maggiolo F., Ripamonti D., Gregis G., Quinzan G., Callegaro A., and Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 18 (2004) 439-446
31. 6 cell/l. AIDS 19 (2005) 53-61
32. Boschi A., Tinelli C., Ortolani P., Moscatelli G., Morigi G., and Arlotti M. CD4+ cell count-guided treatment interruptions in chronic HIV-infected patients with a good response to highly active antiretroviral therapy. AIDS 18 (2004) 2381-2389
33. Miller V. Structured treatment interruptions in antiretroviral management of HIV-1. Curr Opin Infect Dis 14 (2001) 29-37
34. Ahdieh Grant L., Silverberg M.J., Palacio H., Minkoff H., Anastos K., Young M.A., et al. Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS 15 (2001) 2101-2108
35. Tebas P., Henry K., Mondy K., Deeks S., Valdez H., Cohen C., et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 186 (2002) 851-854
36. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344 (2001) 472-480
37. Morales-Lopetegi K. Selection of M184V mutation during repetitive cycles of structured antiretroviral treatment interruption. Antivir Ther 6 Suppl. 1 (2001) S28
38. Tremblay C. HIV evolution during treatment interruptions following early antiretroviral treatment of acute infection. Antivir Ther 6 Suppl. 1 (2001) S17